Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy

BACKGROUND: Natalizumab is a monoclonal antibody approved for the treatment of patients with relapsing-remitting multiple sclerosis. According to the current clinical recommendations, its use during pregnancy should be carefully evaluated only in women with highly active disease who plan a pregnancy...

Descripción completa

Detalles Bibliográficos
Autores principales: Godano, Elisabetta, Barra, Fabio, Allodi, Alessandra, Ferraiolo, Antonella, Laroni, Alice, Novi, Giovanni, Mancardi, Giovanni Luigi, Gustavino, Claudio, Arioni, Cesare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987111/
https://www.ncbi.nlm.nih.gov/pubmed/33757559
http://dx.doi.org/10.1186/s13052-021-01025-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987111/
https://www.ncbi.nlm.nih.gov/pubmed/33757559
http://dx.doi.org/10.1186/s13052-021-01025-4

Ejemplares similares